HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Alison E. Smith; Emanuela Ferraro; Anton Safonov; Cristina Bernado Morales; Enrique J. Arenas Lahuerta; Qing Li; Amanda Kulick; Dara Ross; David B. Solit; Elisa de Stanchina; Jorge Reis-Filho; Neal Rosen; Joaquín Arribas; Pedram Razavi; Sarat Chandarlapaty

doi:10.1038/s41467-021-27093-y

Nature Communications (Nov 2021)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Alison E. Smith,
Emanuela Ferraro,
Anton Safonov,
Cristina Bernado Morales,
Enrique J. Arenas Lahuerta,
Qing Li,
Amanda Kulick,
Dara Ross,
David B. Solit,
Elisa de Stanchina,
Jorge Reis-Filho,
Neal Rosen,
Joaquín Arribas,
Pedram Razavi,
Sarat Chandarlapaty

Affiliations

Alison E. Smith: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Emanuela Ferraro: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Anton Safonov: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Cristina Bernado Morales: Preclinical Research Program, Vall d’Hebron Institute of Oncology
Enrique J. Arenas Lahuerta: Preclinical Research Program, Vall d’Hebron Institute of Oncology
Qing Li: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Amanda Kulick: Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center
Dara Ross: Department of Pathology, Memorial Sloan Kettering Cancer Center
David B. Solit: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Elisa de Stanchina: Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center
Jorge Reis-Filho: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Neal Rosen: Molecular Pharmacology and Chemistry Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
Joaquín Arribas: Preclinical Research Program, Vall d’Hebron Institute of Oncology
Pedram Razavi: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center
Sarat Chandarlapaty: Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center

DOI: https://doi.org/10.1038/s41467-021-27093-y
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 10

Abstract

Read online

Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose genetic activation of MAPK as a resistance mechanism.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal